Bloodwork measures what is happening at the biomarker level. Subjective markers (energy, mood, recovery) are useful for tracking trends, but they cannot show hematocrit, hormone levels, or whether metabolic markers are moving.
The question this page looks at is when a draw is taken, which depends on what is being run and what the draw is meant to show.
The bloodwork timeline
This page lays the timing out in three phases. The specific timing varies by compound.
Baseline: before starting
A baseline panel is taken before the first dose and is the reference point. Without baseline numbers, compound effects cannot be told apart from pre-existing levels. The Xyosted testosterone label, for example, says to check that hematocrit is not elevated before starting.5
First recheck: 4 to 6 weeks
By their labels, semaglutide reaches steady state after 4 to 5 weeks of once-weekly doses and tirzepatide after 4 weeks.12 The Xyosted label measures testosterone trough concentrations after 6 weeks of dosing and says steady state was reached by week 6.5 A draw at that point reflects the regular schedule rather than the ramp-up.
Periodic monitoring
For testosterone, the Endocrine Society guideline describes a standardized monitoring plan that measures serum testosterone and hematocrit and evaluates prostate cancer risk during the first year.4 The Xyosted label says to evaluate hematocrit approximately every 3 months while on treatment.5 Repeated draws show gradual shifts that a single comparison might miss.
Which panels for which compounds
Different compound categories are linked to different biomarkers in their labels and trials.
Testosterone & hormone protocols
Testosterone has a published monitoring plan in the Endocrine Society guideline.4 The Xyosted label says to monitor hematocrit, PSA and lipids, and the Depo-Testosterone label says hemoglobin and hematocrit should be checked periodically with long-term use and that serum cholesterol may increase.56 The guideline recommends a free testosterone measure when total testosterone is near the lower limit or SHBG is altered.4
GLP-1 receptor agonists
The Wegovy label reports mean increases from baseline in amylase of 15% to 16% and lipase of 39% in its weight-reduction trials, and says routine monitoring of serum calcitonin is of uncertain value.3 Glucose and HbA1c are the measures used in the type 2 diabetes labels.1
General peptides (BPC-157, TB-500, GHK-Cu, etc.)
No published monitoring plan was found for healing and cosmetic peptides like these, and they are not measured on standard blood tests. General health markers are the panel left to look at.
GH secretagogues (CJC-1295, ipamorelin, etc.)
In a trial in healthy adults, single injections of CJC-1295 raised mean IGF-I 1.5- to 3-fold for 9 to 11 days.8
Why trough timing matters for hormones
For testosterone, the time of the draw relative to the last dose changes the result. On the Xyosted label (weekly testosterone enanthate under the skin), testosterone peaked a median of 11.9 hours after the dose; at week 12 the mean peak was 790 ng/dL and the mean low point 436 ng/dL.5
The Xyosted label bases dose changes on the trough concentration, measured 7 days after the most recent dose.5 A trough draw taken the same way each time is comparable across time periods: a week-6 trough can be read against a week-12 trough.
Draws at random times relative to the dose are harder to read. A higher reading might mean levels have risen, or only that the draw came closer to the last injection. The same draw timing removes this variable.
With testosterone injected twice a week (say Monday and Thursday), the trough falls on Thursday morning, before the Thursday injection. The saturation level on draw day shows where in the concentration curve the draw was taken.
Fasting requirements
Some markers are read fasted. How much it matters differs by marker:
- Glucose and insulin: fasting glucose and fasting insulin are, by name, fasted tests.
- Lipids: a 2016 European consensus found the largest mean change 1 to 6 hours after usual meals was +0.3 mmol/L for triglycerides, called not clinically significant, and recommends non-fasting samples for routine lipid profiles.9
- Metabolic panels: a fasted draw keeps baseline and later numbers comparable.
For diagnosing low testosterone, the Endocrine Society recommends fasting morning total testosterone.4 Drawing fasted at the same time of day keeps conditions consistent across panels and timepoints.
Where to get bloodwork
Options vary by country, but the general categories are:
- Direct-to-consumer labs: Services that let a person order panels without a doctor's order and walk into a lab for a draw. Availability differs by country.
- GP / Primary care: A doctor can order panels, though compound-specific markers may need context.
- Telehealth clinics: Some TRT and peptide clinics include periodic bloodwork in their service.
Whatever the source, results that include reference ranges, and copies kept over time, allow comparison later.
Reading your results
Two principles for interpreting bloodwork on any protocol:
- Trends matter more than single readings. One high or low value is a data point. A consistent pattern across several draws is a trend.
- Compare to your own baseline, not just the reference range. A reference range describes a population. A pre-protocol baseline describes one person, so it is the closer comparison.
Logging bloodwork results alongside your protocol data (dose history, saturation levels, subjective check-ins) creates a complete picture that none of those data streams provide alone.
References
- Novo Nordisk (DailyMed). Ozempic (semaglutide) injection label. 2026. dailymed.nlm.nih.gov
- Eli Lilly (DailyMed). Mounjaro (tirzepatide) injection label. 2026. dailymed.nlm.nih.gov
- Novo Nordisk (DailyMed). Wegovy (semaglutide) label. 2026. dailymed.nlm.nih.gov
- Bhasin S et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018. pubmed.ncbi.nlm.nih.gov
- Antares Pharma (DailyMed). Xyosted (testosterone enanthate) injection label. 2026. dailymed.nlm.nih.gov
- Pharmacia & Upjohn (DailyMed). Depo-Testosterone (testosterone cypionate) injection label. 2026. dailymed.nlm.nih.gov
- Cardoso LM et al. Acromegaly: biochemical diagnosis. Vitam Horm. 2026. pubmed.ncbi.nlm.nih.gov
- Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov
- Nordestgaard BG et al. Fasting is not routinely required for determination of a lipid profile. Eur Heart J. 2016. pubmed.ncbi.nlm.nih.gov